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Differential expression of long non-coding RNAs (lncRNAs) during differen-
tiation and their misregulation in cancer highlight their potential as cell fate
regulators. While some example lncRNAs have been characterized in great
detail, the functional in vivo relevance of others has been called into question.
Finding functional lncRNAs will most probably require a combination of
complementary approaches that will greatly vary depending on their
mode of action. In this review, we discuss the different tools available to dis-
sect genetically lncRNA requirements and how each is best suited to studies
in particular contexts. Moreover, we review different strategies used to select
candidate lncRNAs and give an overview of lncRNAs described to regulate
development and cancer through different mechanisms.1. Introduction
Regulated gene expression is the basis for the extensive variety of cell types our
bodies generate from the same set of DNA instructions. Specific gene programmes
are transcribed in particular cells providing themwith theirmolecular identity and
the protein products that underlie their functions. Together with coding genes,
thousands of long non-coding RNAs (lncRNAs) are also expressed in a cell-type-
specific manner during differentiation and in certain cancers. This has been
extensively reported in many organisms and cell types [1–4], yet demonstrating
that these molecules play functional roles has not been easy.
The now ever-expanding catalogue of lncRNAs first became apparent from
efforts to annotate the functional features of the human genome, which showed
that the vast majority of the genome was transcribed [5]. Currently, lncRNAs
are defined as capped transcripts longer than 200 nucleotides, which coincides
with the cut-off for many RNA extraction protocols [6]. They can be spliced
and, in most of the published studies, are also polyadenylated. LncRNAs have
little or no coding potential, although some do bind to ribosomes [7–9]. They
were originally described to have equivalent chromatin features to protein-
coding genes [10]. However, more recent work has highlighted differences in
the abundance of particular histone marks [11,12] and splicing efficiency
[12,13] between lncRNAs and coding genes, as well as subsets of lncRNAs that
differ in their chromatin signatures [4,14].
Hundreds of thousands of lncRNAs have been annotated in different
species and tissues [15]. Of those, only a handful have been shown to be critical
for organism development [16–18] or cancer progression [19], and the mechan-
isms by which they act have been established in just a few cases. For some,
biochemical partners have been carefully identified, yet in vivo evidence for
their function is missing or questions have been raised regarding the relevance
of the previously reported mechanisms of action [20,21]. Bridging this gap is
essential for building a solid body of knowledge of how lncRNAs function in
cell fate choices and the mechanisms by which they act. In this review, we
will focus on the different strategies to select and identify functional lncRNAs
and some mechanistic examples of lncRNA acting in differentiation and cancer.
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22. Cell-type-specific expression of long
non-coding RNAs: cause or
consequence?
The cell-type-specific expression observed for lncRNAs has
provoked much excitement, as it implies that they might
function during cell fate decisions. In accord with this notion,
deregulation of lncRNAs has also been widely observed
across human cancers [22–25]. Such disease-associated expres-
sion changes suggested a potential role for these lncRNAs in
driving cancer or at least contributing to maintaining an
aberrant transcriptional landscape.
2.1. Long non-coding RNA expression during
development
Differential expression of lncRNAs has been reported between
regions of themammalian brain [26,27], and lncRNAdynamics
have been analysed in more detail during corticogenesis [28].
Several studies have shown differential expression of lncRNAs
in in vitro differentiation models of haematopoiesis [29,30] and
in freshly isolated cell populations [31,32], as well as during
mammalian adipogenesis [33,34]. This tissue and cell-type-
specific regulation is observed across species, including
during development of zebrafish [2], Caenorhabditis elegans
[3], and even during the life cell cycle of our close unicellular
relative, Capsaspora owczarzaki [4].
If lncRNAs are to regulate key developmental genes, a
very appealing possibility is that they do so in cis. Correlated
expression of lncRNAs and their neighbouring genes has
been reported in embryonic stem (ES) cell differentiation to
endoderm [35] and to embryoid bodies [36], as well as in
human B and T cell lineages [37]. However, neighbour corre-
lation is not a special property of lncRNA–gene pairs, as the
expression levels of neighbouring genes are often correlated.
This is thought to be due to shared regulatory elements affect-
ing each neighbour [38] and to the general neighbourhood or
chromosomal domain around them [39,40].
This leaves us with several possibilities to consider, and a
myriad of experimental challenges to distinguish between
them. The genomic location of lncRNAs and their neighbouring
regulatory elements could determine their cell-type-specific
expression, with the RNA being a mere by-product of the
regulatory mechanisms already in place [41]. On the other
hand, lncRNAs could be critical for expression of those
developmental genes, orchestrating chromatin changes by
specific RNA–protein interactions, or by increasing the local
concentration of transcriptional machinery regardless of the
actual RNA sequence transcribed. A general mechanism by
which lncRNA transcription in specific cell types could reor-
ganize nuclear architecture, and thus contribute to the new
transcription landscape, has even been proposed [15].
2.2. Long non-coding RNA misregulation in cancer
Along the same lines, cancer-specific lncRNA expression
could simply be a by-product of aberrant gene expression
in cancer. However, genetic mutations can directly affect
lncRNA expression, with the lncRNAs themselves playing a
causal role in specific scenarios. LncRNACCAT2, for example,
encompasses a cancer-associated SNP. The risk allele correlateswith a higher expression of the lncRNA, which in turn pro-
motes proliferation in colorectal cancer [42]. This lncRNA is
part of the 8q24.21 region, where many cancer-associated
mutations and amplifications have been reported. Several
disease-associated SNPs and translocations including the
lncRNA PVT1 have drawn researchers’ attention to this very
complex locus [43]. One of these amplifications is that of
PVT1 and its neighbouring gene c-MYC. In breast cancer
models PVT1 RNA levels correlate with MYC protein, yet
PVT1 and c-MYC are not always co-amplified. This suggests
that amplification of this lncRNA alone (even without MYC)
can promote tumorigenesis in breast cancer by increasing
MYC expression [44], which has been proposed to occur by
protein stabilization. However, it is unlikely that this is the
only mechanism of action for this lncRNA as this multi-
exonic transcript encoding over 20 different isoforms is itself
under the control of c-MYC and harboursmultiplemicroRNAs
within its locus [45].
While these are a few well-characterized examples, a
much greater number of functional studies will be required
to tease apart collaterally expressed lncRNAs from those
with important roles both in development and in cancer.3. Finding functional long non-coding
RNAs
Many experimental strategies have been used to dissect
genetically lncRNA requirements in differentiation and
cancer. Powerful in their own ways, each of these techniques
has its own drawbacks. Therefore, a combination of comp-
lementary approaches will probably be required to reveal
the biological impact of lncRNAs. The choice of approach
also strongly depends on the biological question, whether it
is the identification of lncRNAs important for a differentiation
or disease process, the study of specific types of regulatory
mechanisms—cis versus trans, or an in-depth analysis of a
particular lncRNA.
3.1. Different tools for different questions
The main consideration is that, in a particular lncRNA locus,
the act of transcription itself could be key to establishing or
maintaining the chromatin state of the surrounding area,
while, in this scenario, the actual sequence of the RNAwould
be irrelevant. Or the RNA itself could be the functional unit,
having some sequence-dependent interactions with proteins,
RNAs or DNA elements. It could even be that both thesemech-
anisms apply for the same locus. Therefore, it is very important
to understand each experimental set-up and what it tells us
about each particular lncRNA.
Several studies have taken advantage of RNA interference
(RNAi) approaches, either transduced shRNAs or transfected
siRNAs [46,47]. This strategy has been coupled with a pheno-
typic readout, such as viability or differentiation, to identify
lncRNAs where the RNA molecule itself is important
(figure 1). However, many worry about potential off-target
effects (though this is no different from shRNA studies with
protein-coding genes). There are additional concerns regarding
the difficulty of knocking down lncRNAs that are chromatin-
associated versus cytoplasmic, given that small RNA loading
into the RISC complex takes places in the cytoplasm. While
there is some evidence for differences in knockdown efficiency
interference with
RNA/transcription  
knockdown
terminator insertion
genome
editing
promoter/locus deletion
CRISPRi
Figure 1. Different approaches for disrupting lncRNAs. Methods such as knockdown and CRISPRi affect the RNA itself or reduce the transcription of the lncRNA.
Knockdown can be achieved in a variety of ways (siRNA, shRNA, LNA, ASO). CRISPRi is most efficient if Cas9 is fused to repressor domains (e.g. KRAB). These
methods can also be transient. Insertion of an early terminator sequence or complete deletion of the locus or promoter are achieved via genome engineering
and are non-reversible.
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3depending on subcellular location [48], this concern would
apply only to lncRNAs that are never exported to the cyto-
plasm. LncRNAs that function in the nucleus but in trans
could very well be exported just like other RNAs and then
re-imported. Undoubtedly, themain advantage of knockdown
is that it allows for high-throughput screens that could yield a
list, though potentially incomplete, of lncRNAs with functions
in the phenotypic assay of our choice.
To circumvent possible subcellular localization biases, other
researchers have taken advantage of alternative knockdown
techniques, independent of the RNAi machinery, that do not
require processing in any specific cell compartment. Morpholi-
nos targeting splice junctions or conserved regions have been
used in zebrafish for identification of functional lncRNAs
in vivo [16]. Locked nucleic acids (LNAs) have also been used
in mammalian cells [49,50]. Both of these approaches rely on
annealing a synthetic nucleic acid to the lncRNA and blocking
its function or its splicing. Antisense oligos (ASOs) are another
alternative that takes advantage of RNase-H activity. ASOs
have been used in a variety of systems, both delivered to cul-
tured cells and administered in vivo in mice [19,51]. Several
ASOs have now been approved for clinical use and, although
their targets so far have been coding genes, this opens up
the path towards therapeutic targeting of lncRNAs. These
approaches, although incredibly useful because they exclu-
sively target the RNA, can only be deployed where these
molecules can be injected or otherwise delivered. This would
not allow for pooled high-throughput screening and misses
out on the advantages of genetically encoding knockdown,
which can be conditionally induced for in vivo studies.
The ultimate proof of functionality is a genetic knockout.
They allow for the study of in vivo function and reduce the
possibility of off-target effects. Discrepancies between
the hypothesized mechanisms for some lncRNAs based on
the in vitro data and the absence of or very mild phenotypes
observed in knockout animals [20,52–54] have resulted in
scepticism regarding broad regulatory roles for lncRNAs [55].
Two recent examples of lncRNA knockouts emphasize
how, in some cases, phenotypesmight bemore context-specific
than anticipated.Malat1 is a very abundant lncRNA that loca-
lizes to nuclear speckles. Although it was hypothesized that
this RNA was required for speckle or paraspeckle formationand maintenance and regulated alternative splicing through
interaction with SR proteins [56], three independent mouse
knockout models showed that Malat1 was dispensable for
viability [52–54]. Furthermore, Malat1 was shown not to be
required for nuclear speckle formation and its deletion did
not affect SR protein phosphorylation [54]. However, when
crossed with the MMTV-PyMT mouse model of human
breast cancer, Malat1 deletion impaired tumour progression
as evidenced by a severe reduction in metastatic burden [19].
LincRNA-EPSwas shown to have an anti-apoptotic role and
be required for red blood cell development in tissue culture
models of erythroid development [57]. The knockout mouse
model for this lncRNA showed no defects in blood develop-
ment. However, LincRNA-EPS controls expression of immune
response genes in macrophages and proved essential for the
animals to respond to endotoxin challenge [21].
Although their molecular mechanisms still remain to be
elucidated, these RNAs are representative examples of how,
just as for coding genes, some lncRNAs could play roles
under particular stress or disease conditions. This could
potentially be the case for other lncRNAs, whose proposed
roles have met with controversy, such as HOTAIR, where
knockout animals seem to be viable and healthy [20,58].
When removing a DNA locus to generate a knockout—
especially when dealing with large deletion—any phenotype
observed could be due either to loss of an encoded RNA or
to deletion of DNA sequences that might include regulatory
elements. For this reason, full transcript knockouts can be
combined with complementary strategies to dissect roles
of RNA from those of DNA elements. The possibilities of
genome engineering are not limited to full locus knockout,
but instead allow more subtle modifications, such as polyade-
nylation (poly-A) signal insertions for premature termination
(figure 1). Taking advantage of CRISPR/Cas9, a recent study
looked at whether a set of 12 lncRNAs regulated the expression
of their neighbouring genes in cis. Although expression defects
were observed upon promoter knockout for five lncRNAs,
only one had the same effect when a poly-A signal was
inserted, suggesting that only the regulatory elements in the
DNA surrounding the promoter and not the RNAs were
required for these cis effects [59]. An equivalent mechanism
has been proposed to explain the differences between knockout
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4and poly-A insertions for the lncRNA Lockd and its neighbour
gene Cdkn1b [60].
Two independent models for Fendrr knockout showed that
it was required for mouse development [17,18]. Interestingly,
the phenotypes differed, one being embryonic lethal with a
presumed requirement for lateral plate mesoderm [17], while
the other was perinatal lethal [18]. These differences could be
the consequence of the distinct genetic strategies, one being a
triple polyadenylation insertion and the other one a whole
gene replacement, emphasizing the need for complementary
approaches that distinguish betweenDNA and RNA elements.
The scenario is substantially more complicated when the
lncRNA and its target gene have overlapping transcripts.
Airn overlaps in antisense with the imprinted gene Igfr2.
Through a series of polyadenylation cassette insertions, it
was shown that transcriptional termination of Airn only
leads to Igfr2 de-repression when the non-coding transcript
no longer overlapped the Igfr2 promoter. This work concluded
that transcription of Airn, rather than the final transcript, is
responsible for promoter silencing [61]. Combinations of pro-
moter, exon knockouts and termination signals created using
CRISPR/Cas9 have helped dissect the relationship between
Haunt (also known as linc1547 or linc-Hoxa5) and the HoxA
locus. Knockdown, termination or deletions of the first exons
lead to increased expression of HoxA genes during retinoid
acid-induced differentiation of ES cells, supporting a repressive
role for Haunt at the HoxA genes. However, deletion of the
whole Haunt locus prevents expression of HoxA, presumably
due to deletion of some regulatory DNA elements required
for HoxA induction [62].
While more accessible owing to the advancements in
genome engineering, mouse model generation is still not
amenable to high-throughput studies, and therefore requires
careful selection of lncRNA candidates. Genome-scale strat-
egies for lncRNA CRISPR/Cas9 deletion are being developed
[63], and variations in the ever-expandingCRISPR/Cas9 toolkit
could help identify functional lncRNAs. Cas9 fused to repres-
sors [64] or activators [65] now allows for the manipulation of
expression levels at the loci themselves (figure 1). Using the
former approach, researchers have identified human lncRNAs
essential for cell growth in a diverse set of cell lines [64]. This
technology is scalable and could help identify lncRNAs
required in a variety of contexts by performing loss-of-function
studies. The main limitation is that altering the chromatin state
of the lncRNA promoter could directly affect nearby genes,
complicating the interpretation of the phenotype.
3.2. Which long non-coding RNAs to study
The primary approach will depend on the biological question
being asked. Some studies directly focus on a particular
lncRNA of interest, while others aim at the unbiased identifi-
cation of lncRNAs important for a process. Different strategies
have been employed to select subsets of lncRNAs for study
based on their expression level, dynamic regulation, tissue
expression and even conservation.
Historically, highly abundant lncRNAs were chosen as
representatives of this RNA class, with the hope of identify-
ing possible mechanisms by which lncRNAs might act
generally. This was, in part, due to experimental convenience
and technical limitations, and this class includes the best
characterized lncRNA to date, Xist, as well as Malat1, and
Neat1. Xist orchestrates X chromosome inactivation. Expressedfrom the silenced allele, this lncRNA acts in cis to inactivate the
expression of that X chromosome copy [66]. Focusing on a par-
ticular lncRNA has allowed researchers to channel all their
efforts towards a mechanistic understanding of its mode of
action, while also developing in vivo tools for its study. While
in vivo functional validation is everyone’s dream, placing all
eggs in one basket is always risky and can lead to disappointing
outcomes [20,52,53].
The opposite approach to studying a single lncRNA is
genome-wide unbiased screening of lncRNAs. This can be
an excellent filter to identify potential functional lncRNAs,
building a resource for further mechanistic studies, although
this approach is best suited to easily measured phenotypes,
such as proliferation. Genome-wide screens have been used
to identify lncRNAs essential for human cancer cell growth
or survival [64], or those required in mouse ES cell self-
renewal [47]. In ES cells, this approach identified TUNA, a
lncRNA required for neural specification from ES cells that
had already been described to have neural phenotype in
zebrafish (named Megamind) [16], validating this strategy.
LncRNA annotation can be intersected with expression
levels if one wishes to reduce the number of targeted lncRNAs.
This can be necessary for more elaborate phenotypic assays that
are not as scalable. A straightforward approach is to assess only
the lncRNAs expressed in the cell type or tissue by setting
some minimal expression cut-off [46]. However, for some strat-
egies further reduction of lncRNA candidates is necessary. By
analysing expression in different related tissues, especially in
developmental systems, several groups have focused only on
differentially regulated lncRNAs. The rationale behind this is
that a transcript dynamically induced or silenced during a cell
fate transition, for example, is more likely to be important for
that process. Differential expression helped in the selection
of candidates in epidermal differentiation [67,68], cardiac
differentiation [69] and haematopoiesis [32].
Another extremely useful layer of filtering is evolutionary
conservation.Although their sequence isnotbroadly conserved,
lncRNAs can often be found in syntenic positions in different
species. These ‘syntelogs’ can even share some small conserved
domains [70]. This approach has been used to identify several
conserved lncRNAs that act during zebrafish development
[16] and drew researchers’ attention to NORAD, a conserved
lncRNA in mammals that modulates Pumilio proteins [71,72].
Combined with differential expression, conservation can help
focus the candidate list on lncRNAswith key functions in devel-
opmental or disease processes. As ‘syntenic conservation’ is a
rather loose criterion and the presence of a lncRNA does not
necessarily indicate that itwill have the same function inadiffer-
ent organism, complementary strategies will be very helpful in
identifying orthologous lncRNAs. If they are functionally con-
served, lncRNA ‘syntelogs’ might share structure similarities,
even if they do not share much sequence identity. Some studies
have approached this by looking at predicted secondary RNA
structure [73]. Although RNA structure predictions for long
RNAs might not be particularly useful, new experimental
approaches to globally identify structure features in lncRNAs
could aid in this task [74].
When dealing with lncRNA annotation, it is important to
be aware of the limitations. Although most assemblies set up
stringent coding potential cut-offs, lncRNAs often contain
very short open reading frames (ORFs). The functionality of
these micropeptides is hard to assess unless one addresses
it experimentally. Three different short proteins have been
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Figure 2. Themes in lncRNA functions. LncRNAs have been described to play multiple roles affecting gene expression at the transcriptional level via interactions
with chromatin remodelling complexes, direct binding to the DNA as an RNA–DNA triplex, or facilitating chromatin looping (a), interacting with RNA processing
machinery or affecting mRNA stability (b) or directly regulating protein function (c).
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5found to play a role in muscle function or regeneration
[75–77], which emphasizes the importance of testing for
RNA-mediated rather than protein-mediated effects.
Overall, the ability to modulate the expression of lncRNAs
or disrupt it altogether now allows an assessment of lncRNA
requirements in many developmental and cancer contexts.
This, combinedwith some clever candidate selection strategies,
has identified a number of lncRNAs important in these
processes. The level of current mechanistic understanding for
each of these lncRNAs is variable, yet the techniques available
and being developed hint at a promising future.4. Long non-coding RNAs shape
development and cancer
Even for well-studied lncRNAs, our mechanistic under-
standing has deepened only in the last few years. The poster
child for lncRNA researchers,Xist, orchestrates X chromosome
inactivation. The functional properties of Xist and the order of
events it directs have been known for decades (reviewed in
[66]). However, it has taken until very recently to better under-
stand the X inactivation at the molecular level. We now know
the protein partners Xist requires for X chromosome silencing
[78,79], how Xist spreads [80] and takes advantage of the
chromosome’s three-dimensional structure to initiate silencing
[81], and how that chromosomal conformation changes during
transcriptional silencing [82,83]. Additionally, this RNA is
modified with N6-methyladenosines, which contribute to its
transcriptional repressive activity [84]. Xist illustrates not
only the detailed mechanistic understanding to which we
can aspire for other lncRNAs of interest but also the tremen-
dous amount of effort required to understand even a single
lncRNA. Of note, Xist is also highly abundant when it is
expressed, and that induction takes place in a cell type wecan culture in large amounts (ES cells). Greater challenges
can be expected with lncRNAs expressed to lower levels in
very specific cell types.
Some hints at how other lncRNAs exert their functions in
development and cancer have been reported. Although the
field is still maturing, lncRNAs have been described to play a
myriad of roles, from regulating gene expression to regulat-
ing mRNA processing or affecting protein stability (figure 2).
There are also several examples of lncRNA loci where the act
of transcription but not the RNA itself seems to be of
functional relevance [59,85] or where transcription is even
dispensable [59]. Here, we focus on the RNAs themselves as
the functional units.
4.1. Effects on chromatin and DNA interactions
Following Xist’s example, many researchers have focused on
potential chromatin regulatory roles of lncRNAs. Mistral
(Mira) is a lncRNA expressed in ES cells that is reported to inter-
act with MLL1 to recruit this protein to Hoxa6 and Hoxa7,
leading to their activation. Consequently, siRNA-mediated
knockdown of Mistral leads to reduced transcription of these
genes and negation of the overall germ-cell specification pro-
gramme [86]. Also expressed in ES cells, HoxBlinc binds to the
same complex to promote HoxB transcription and mesoderm
specification [87].
Two lncRNAs have been shown to be required for heart
development. Braveheart, required for the production of con-
tracting embryoid bodies from ES cells, interacts with the
Polycomb factor SUZ12 [69], while Fendrr, a lncRNA essential
for mouse development [17,18], binds to SUZ12 as well as
EZH2 and WDR5 [17]. These interactions with members of
the TrxG/MLL and Polycomb complexes place these lncRNAs
in a position to direct chromatin modifications to particular
DNA loci in a sequence-specific manner (figure 2a).
rsob.royalsocietypublishing.org
Open
Biol.7:170121
6Following this hypothesizedmechanism, it was shown that
Fendrr interacts, at least in vitro, with the promoter regions of
Pitx2 and Foxf1, both of which are expressed during heart
development [17]. In HeLa cells, Khps1 regulates the promoter
of its antisense gene, the proto-oncogene SPHK1, by forming a
DNA–RNA triplex at its promoter while recruiting p300/CBP
[88] (figure 2a). TARID also regulates its antisense gene, TFC21,
by guiding GADD45A to the locus and promoting demethyla-
tion, which leads to gene activation. TARID and TCF21 are
silent and heavily covered by DNA methylation in non-small
cell lung cancer (NSCLC), head and neck squamous cell carci-
nomas (HNSCC) and ovarian cancers (OVC) [49]. And
although direct RNA–DNA binding has not been shown,
lncRNA SLNCR1 is required for bringing androgen receptor
to the MMP9 promoter, which increases MMP9 expression
and leads to melanoma invasion [89].
The ultraconserved lncRNA Megamind/TUNA showed
brain development phenotypes upon knockdown in zebrafish
[16] and is required for ES cell pluripotency and neuronal
differentiation from mouse ES cells [47]. In the mouse, this
lncRNA binds three RNA-binding proteins and interacts with
the Sox2 promoter [47]. Sox2 is a key transcription factor in
neuronal differentiation, so its regulation could explain the
resulting phenotype. And while the interaction seems to be
indirect, Dali has been shown to localize globally to active
promoters in the N2A neuronal differentiation model [90], as
shown by CHART-seq [91].
Interaction with transcription factors themselves is another
plausible mechanism to promote expression of specific gene
programmes. RMST, for example, is a lncRNA up-regulated
during neurogenesis that interacts with Sox2. Knockdown of
RMST leads to a reduction in Sox2 ChIP-seq peaks in this
model,which suggests that this lncRNA is somehow facilitating
the binding of this transcription factor [92].
Additionally, LUNAR and DEANR1 both seem to function
by facilitating DNA looping between the lncRNA locus and
their target gene to promote activation. LUNAR is a Notch-
regulated lncRNA that activates the IGFR1 gene in T-cell
acute lymphoblastic leukaemia [51], while DEANR1 functions
via a similar mechanism in endoderm development, activating
FOXA2 expression through the recruitment of SMAD2/3 [93]
(figure 2a).
4.2. Effects on mRNA stability and processing
Conceptually, the next level of regulation would be for
lncRNAs to negatively or positively affect the stability or
processing of coding mRNAs. By having cell-type or tumour-
specific expression, lncRNAs would effectively control the
output levels for these genes. In accord with this model, a few
exemplar lncRNAs have been shown to interact with hetero-
geneous nuclear ribonucleoproteins (hnRNPs) (figure 2b).
LincRNA-p21, induced in response to DNA damage, interacts
with hnRNP-K, and it is regulated by p53. Knockdown of this
lncRNA leads to up-regulation of genes normally repressed
by p53 and also reduces apoptosis similarly to p53 knockdown
[94]. This suggests a model whereby this lncRNA acts as a
repressor of p53-dependent genes.
In neural differentiation, Pnky knockdown leads to progeni-
tor expansion, and mass spectroscopy of lncRNA-interacting
proteins followed by immunoblotting validation revealed
PTBP1 as one of its interaction partners. Knockdown of this
lncRNA leads to misexpression and altered splicing of manykey genes [95]. Both PTPB1 and hnRNP-K also bind TUNA
during in vitro neuronal differentiation [47]. Being highly
expressed and broadly acting proteins, it is only reasonable to
wonder whether these functions are truly specific. Only more
detailed biochemical studies will be able to clarify this.
In a complementary approach to mass spectroscopy,
protein microarrays identified STAU1 as the interacting part-
ner of lncRNA TINCR [68]. Combined knockdown of TINCR
and STAU1 seems to affect the stability of important epider-
mal differentiation genes such as Krt80 [68], which would
explain its essential role in skin differentiation. During
muscle differentiation, LncMyoD binds IGF2 mRNA-binding
protein 2 (IMP2), which leads to enhanced translation of
mRNAs involved in proliferation. Interestingly, this is a con-
served lncRNA and the mouse and human sequence can
rescue each other’s knockdown [96] (figure 2b).
Rather than binding elements of the RNA processing
machinery as a way to regulate the fate of coding mRNAs,
other lncRNAs have been shown to act as endogenous com-
petitors for microRNAs, thus dampening the silencing of
microRNA targets. LncND, for example, is a primate-conserved
lncRNAexpressed in neural progenitors anddown-regulated in
neurons. This lncRNA competes for miR-143-3p, which would
normally target Notch. Relieving Notch silencing promotes
neuronal differentiation [97].
In the cancer context, LINC00152 acts as an oncogenic
lncRNA, competing with HIF1-a for miR-138. Expression of
this lncRNA promotes invasion in gall bladder cancer [98]. As
an additional example, linc-223 would usually bind to miR-
125-5p but it is down-regulated in acute myeloid leukaemia,
leading to increased repression of IRF4, a target of miR-125-5p
[99] (figure 2b).
The range of action of lncARSR extends even further
because, apart from competing with mir-34 and miR-449
thus promoting stability of AXL and c-MET, this lncRNA can
be packaged into exosomes to be secreted. Down-regulation
of microRNA target genes renders renal cancer cells resistant
to sunitinib, and secretion of the lncRNA can disseminate
this property to neighbouring cells [50].
4.3. Effects on protein stability and function
Rather than affecting themRNAs of genes important for differ-
entiation or malignant proliferation, lncRNAs can also directly
bind proteins essential for a signalling pathway and modulate
their function. Lnc-DC, for example, is induced during den-
dritic differentiation from human monocytes. This lncRNA
interacts with STAT3 and, when knocked down, leads to a
reduction in Y705 phosphorylation of STAT3, decreasing its
nuclear translocation. For that reason, expression of lnc-DC is
required for differentiation of dendritic cells [100] (figure 2c).
Similar protein–lncRNA relationships have been observed
in different cancer models. FAL1 and PVT1 are amplified in
ovarian and breast cancer, respectively. FAL1 associates with
Bmi1, and FAL1 knockdown leads to a reduction in Bmi1
levels and misregulation of large numbers of genes involved
in cell cycle progression [101]. PVT1 has a similar relationship
with the oncogene C-MYC, promoting the stability of this
protein [44] (figure 2c).
lncRNA-LET and LINK-A have opposing effects on HIF1-a
in hepatocellular carcinoma. Enforced expression of lncRNA-
LET leads to reduced HIF1-a and results in lower metastatic
potential [102], while LINK-A interacts with tyrosine protein
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7kinase 6 to promote stabilization of HIF1-a in triple negative
breast cancer [103].
Other lncRNAs have specific roles in particular pathways,
such asMAYA, a lncRNA recruited by HER3-ROR1 that then
binds directly to NSUN6, preventing methylation of MST1.
In breast cancer, MST1 is inactivated by this methylation
resulting in YAP signalling target activation and increased
bone metastasis [104] (figure 2c). SAMMSON is involved in
regulating mitochondrial integrity by associating with p32.
Knockdown of this lncRNA results in aberrant mitochon-
drial structures in melanoma, a cancer where SAMMSON is
amplified [105].
By playing roles in essential cell functions, other lncRNAs
also affect cancer progression. NORAD is a conserved
lncRNA with repetitive regions that binds to PUMILIO pro-
teins [71]. When this lncRNA is absent, PUMILIO proteins
carry out their roles as negative regulators of mRNA stability
and translation, and this results in aneuploidy [72]. LINP1
interacts with Ku80 and DNA-PKcs, coordinating the
non-homologous end-joining (NHEJ) pathway. Apart from
providing essential functions for any cell, this pathway is
particularly required in triple negative breast cancer [106].5. Concluding remarks
lncRNAs are being heavily studied in the context of develop-
ment and cancer, as their unique properties could allow them
to interact with multiple proteins via three-dimensional struc-
tures and also recognize other nucleic acids by base pairing.
Their specific expression during differentiation and disease
places them in an ideal position to play key regulatory roles.
Because of the added complexity in studying lncRNA loci, a
combination of genetic approaches is often required todistinguish between the function of the RNAmolecule and the
regulatory activity from a DNA element in that locus. Many
examples have been described for lncRNAs interacting with
chromatin, regulatinggenes at theRNAorprotein level, or inter-
fering globally with splicing. These functions are diverse and
expand the original hypothesis of a nuclear-specific function
for most lncRNAs. It was also proposed that lncRNAs would
mostly act in cis, as their expressionmirrored that of their neigh-
bour genes [36,37,107,108]. Although that is the case for some
examples, it does not seem to be a general rule [59].
LncRNAs are diverse molecules that are not likely to fit in
one functional class. Consequently, we should start thinking
of them more like proteins, some functioning in the nucleus
[109], others acting in the cytoplasm and others supporting
the structure of cells [110,111]. What is becoming clearer with
the development of in vivomodels and our expandingmechan-
istic understanding is that there are lncRNAs with essential
functions in development and others required for cancer pro-
gression, taking this class of RNAs out of the ‘junk DNA’
category once and for all. Not every annotated lncRNA will
have an RNA-mediated function—or a function at all—but
identifying the biologically relevant ones and understanding
their mechanisms will certainly be a hotbed for future study.Data accessibility. This article has no additional data.
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